Trial Profile
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Losartan (Primary)
- Indications HIV-1 infections
- Focus Pharmacodynamics
- 08 May 2020 Results (n=13) comparing compare the Lymphoid Tissue pharmacokinetics of TFV-DP following a switch from TDF to TAF in HIV-infected persons, published in the Clinical Pharmacology and Therapeutics.
- 29 Mar 2019 Status changed from active, no longer recruiting to completed.
- 09 Oct 2018 Planned End Date changed from 1 Jul 2018 to 1 Dec 2018.